The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Related to this article
Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.
The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Dr Geyer on the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD
4
Dr Vachhani on Phase 2 Efficacy/Safety Data for Sapablursen in Polycythemia Vera
5